WO2005026131A1 - Transition state structure and inhibitors of thymidine phosphorylases - Google Patents

Transition state structure and inhibitors of thymidine phosphorylases Download PDF

Info

Publication number
WO2005026131A1
WO2005026131A1 PCT/US2004/028703 US2004028703W WO2005026131A1 WO 2005026131 A1 WO2005026131 A1 WO 2005026131A1 US 2004028703 W US2004028703 W US 2004028703W WO 2005026131 A1 WO2005026131 A1 WO 2005026131A1
Authority
WO
WIPO (PCT)
Prior art keywords
transition state
compounds
salts
acid ester
thymidine phosphorylase
Prior art date
Application number
PCT/US2004/028703
Other languages
French (fr)
Inventor
Vern L. Schramm
Matthew R. Birck
Peter C. Tyler
Richard H. Furneaux
Gary B. Evans
Original Assignee
Albert Einstein College Of Medicine Of Yeshiva University
Industrial Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine Of Yeshiva University, Industrial Research Limited filed Critical Albert Einstein College Of Medicine Of Yeshiva University
Priority to EP04783065A priority Critical patent/EP1673353A4/en
Priority to US10/570,475 priority patent/US20070275988A1/en
Priority to JP2006525465A priority patent/JP2007504246A/en
Publication of WO2005026131A1 publication Critical patent/WO2005026131A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)

Definitions

  • the present invention generally relates to enzyme inhibitors. More specifically, the invention relates to the transition state structure of thymidine phosphorylase and its use as a blueprint for the design of transition state analog inhibitors of thymidine phosphorylases, the transition state analog inhibitors of thymidine phosphorylase, and methods of using those inhibitors.
  • Nucleoside phosphorylases play an integral role in several types of human cancers.
  • PNP purine nucleoside phosphorylase
  • thymidine phosphorylase aka platelet derived-endothelial cell growth factor; PD-ECGF
  • PD-ECGF platelet derived-endothelial cell growth factor
  • TP is the primary enzyme of fluoropyrimidine antimetabolite (for example 5-fluoiO-2'-deoxyuridine [FdUrd]) degradation.
  • fluoropyrimidine antimetabolite for example 5-fluoiO-2'-deoxyuridine [FdUrd]
  • the fluoiOpyrimidines are one of the most frequently used chemotherapeutic drugs for the treatment of GI malignancies, including colorectal cancer.
  • One approach used clinically to treat liver metastases arising from colorectal cancer is the hepatic artery infusion of FdUrd.
  • FdUrd is converted to its active metabolite, FdUMP, by thymidine kinase.
  • the opposing reaction catalyzed by TP, converts FdUrd to 5-fluorouracil (FUra). Since FUra is 100 to 1000-fold less potent than FdUrd, the metabolism of FdUrd by TP tends to reduce the activity of the anticancer drug. TP inhibitors would thus be useful clinically when used in combination with FrUrd to potentiate its antitumor activity, particularly in more aggressive tumors that express high levels of TP.
  • the inventors have established the transition state structure of thymidine phosphorylase.
  • the transition state structure provides a blueprint to design thymidine phosphorylase inhibitors that resemble that transition state structure. These inhibitors are useful, for example, in inhibiting angiogenesis and in cancer treatments.
  • the invention is directed to transition state inhibitors of a thymidine phosphorylase.
  • the transition state inhibitors are compounds that resemble the charge and geometry of the thymidine phosphorylase transition state.
  • the invention is directed to methods of inhibiting a thymidine phosphorylase.
  • the methods comprise combining the thymidine phosphorylase with any of the transition state inhibitors described above. Additionally, the invention is directed to methods of treating cancer in a mammal. The methods comprise administering to the mammal any of the transition state inhibitors described above. The invention is also directed to methods of inhibiting angiogenesis in a mammal. These methods also comprise administering to the mammal any of the transition state inhibitors described above. The invention is additionally directed to methods of designing an inhibitor of thymidine phosphorylase. The methods comprise designing a compound that resembles the charge and geometry of the thymidine phosphorylase transition state.
  • FIG. 1 provides the thymidine phosphorylase reaction.
  • FIG. 2 provides preferred examples of thymidine phosphorylase inhibitors that are transition state analogs.
  • FIG. 3 provides a schematic of chemical methods for synthesizing radiolabeled thymidine.
  • Panel a Synthesis of ATP from glucose.
  • Panel b Synthesis of thymidine from ATP. Compounds shown in boldface type are purified.
  • AD adenosine deaminase
  • AK adenylate kinase
  • AP alkaline phosphatase
  • APRT adenosine phosphoribosyl transferase
  • G6PDH G6P dehydrogenase
  • 6PGDH 6-phosphogluconate dehydrogenase
  • HK hexokinase
  • PK pyruvate kinase
  • PNP purine nucleoside phosphorylase
  • PPase inorganic pyrophosphatase
  • PRI phosphoriboisomerase
  • PRPS 5-ribosyl-l-pyrophosphate synthesis
  • RTR ribonucleotide triphosphate reductase
  • TP thymidine phosphorylase.
  • FIG. 4 shows a graph of experimental results of the arsenolysis of thymidine by TP.
  • FIG. 5 shows the intrinsic K
  • FIG. 6 shows the experimentally derived model of the TP transition state structure.
  • FIG. 7 shows examples of compounds subjected to electron potential mapping and determination of ability to inhibit thymidine phosphorylase.
  • the present invention is based on the discovery of the transition-state structure of thymidine phosphorylase (TP).
  • TP thymidine phosphorylase
  • the experimental results leading to the discovery of the transition-state structure is described in Example 1.
  • the discovery of the TP transition-state structure allows the design of transition-state analogs that would be expected to be strong inhibitors of TP. This is established by studies of a related enzyme, purine nucleoside phosphorylase (PNP), showing that transition-state analogs having a similar charge and geometry as the transition state compound of an enzyme are likely to be strong inhibitors of that enzyme (Kicska et al. 2001).
  • PNP purine nucleoside phosphorylase
  • the transition state of TP has a surprising structure, since there is apparently little oxacarbenium charge buildup, whereas the transition state was expected to be an oxacarbenium ion (Cole et al., 1999). Accordingly, in some embodiments, the invention is directed to transition state inhibitors of a thymidine phosphorylase (TP).
  • the transition state inhibitors are compounds that resemble the charge and geometry of the thymidine phosphorylase transition state.
  • Non-limiting examples of TP transition state inhibitors are provided as compounds 1-22 of FIG. 2 and compounds 23-32 of FIG. 7. More preferred inhibitors are compounds 9-12, 23, 26, and 29, because those compounds most closely resemble the TP transition state.
  • FIG. 2 is shown as the phosphonic acid, other salt forms are equally effective, and that they will exist in biological fluids and in buffered aqueous solutions as mixtures of salt and acid forms depending upon the biological fluid or buffer. It would also be understood that the inhibitor compounds of FIG. 2 and FIG. 7 may also be in the form of phosphonic acid ester derivatives and that these will constitute pro-drug forms of these compounds, capable of being converted to the active forms by ester cleavage. As used herein, a compound resembles the charge and geometry of the TP transition state if the compound is as much alike in charge and geometry of the TP transition state as any of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG. 7.
  • transition state inhibitors of these embodiments would be expected to inhibit a thymidine phosphorylase from any archaeal, bacterial or mammalian species (including humans), since the enzyme is very similar structurally between kingdoms (Cole et al., 1999).
  • TP transition state inhibitors can be formulated in a pharmaceutically acceptable excipient, for pharmaceutical administration to a mammal, including humans. These formulations can be prepared for administration without undue experimentation for any particular application.
  • the inhibitor compositions can also be prepared alone or in combination with other medications, such as chemotherapeutic agents. Additionally, proper dosages of the inhibitors can be determined without undue experimentation using standard dose- response protocols. Accordingly, the inhibitor compositions designed for oral, lingual, sublingual, buccal and intrabuccal administration can be made without undue experimentation by means well known in the art, for example with an inert diluent or with an edible carrier.
  • the compositions may be enclosed in gelatin capsules or compressed into tablets.
  • the pharmaceutical inhibitor compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.
  • Tablets, pills, capsules, troches and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents.
  • binders include microcrystalline cellulose, gum tragacanth or gelatin.
  • excipients include starch or lactose.
  • disintegrating agents include alginic acid, corn starch and the like.
  • lubricants include magnesium stearate or potassium stearate.
  • compositions of the present invention can easily be administered parenterally such as for example, by intravenous, intramuscular, intrathecal or subcutaneous injection, either alone or combined with another medication, e.g., a chemotherapeutic agent. Parenteral administration can be accomplished by incorporating the compositions of the present invention into a solution or suspension.
  • Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents.
  • Parenteral formulations may also include antibacterial agents such as for example, benzyl alcohol or methyl parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added.
  • the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
  • Rectal administration includes administering the pharmaceutical inhibitor compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas.
  • Suppository formulations can easily be made by methods known in the art. For example, suppository formulations can be prepared by heating glycerin to about 120 °C, dissolving the composition in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold.
  • Transdermal administration includes percutaneous absorption of the inhibitor composition through the skin. Transdermal formulations include patches (such as the well-known nicotine patch), ointments, creams, gels, salves and the like.
  • the present invention includes nasally administering to the mammal a therapeutically effective amount of the inhibitor composition.
  • nasally administering or nasal administration includes administering the composition to the mucous membranes of the nasal passage or nasal cavity of the patient.
  • pharmaceutical compositions for nasal administration of a composition include therapeutically effective amounts of the composition prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the composition may also take place using a nasal tampon or nasal sponge.
  • the invention is directed to methods of inhibiting a thymidine phosphorylase with transition state analogs.
  • the methods comprise combining the thymidine phosphorylase with any transition state inhibitor that resembles the charge and geometry of the TP transition state.
  • the inhibitor is first designed to resemble the transition state and then synthesized.
  • the transition state inhibitor is one of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG. 7, their salts, or their phosphonic acid ester derivatives. More preferably, the transition state inhibitor is one of compounds 9-12, 23, 26, or 29, their salts, or their phosphonic acid ester derivatives.
  • thymidine phosphorylase i.e., from any bacterial, archaeal, or eukaryotic species
  • the thymidine phosphorylase is a mammalian, and most preferably a human thymidine phosphorylase, since the enzyme has a clear effect on mammalian angiogenesis, and is associated with human disease, in particular cancer. Consequently, although these methods could be utilized with thymidine phosphorylases in vitro, it would be expected that the methods would have their greatest usefulness with thymidine phosphorylases in a living cell, most preferably a cell that is part of a living mammal.
  • angiogenesis for example cancer, in particular colon cancer, colorectal cancer, gastrointestinal cancer, and adenocarcinoma (Aoki et al., 2002; Tokunaga et al.,
  • the cancer tissue expresses thymidine phosphorylase (Igawa et al., 2003).
  • the human is being treated with a chemotherapeutic nucleoside substrate of the thymidine phosphorylase, e.g., 5-fluoro-2'- deoxyuridine.
  • the human in need of inhibition of thymidine phosphorylase can alternatively have a disease characterized by excessive or inappropriate angiogenesis, for example rheumatoid arthritis, retinal diseases such as diabetic retinopathy and age related macular degeneration, atherosclerosis, various diseases of female reproductive organs such as endometriosis, or obesity.
  • the invention is directed to methods of treating cancer in a mammal.
  • the methods comprise administering to the mammal a transition state inhibitor that resembles the charge and geometry of the TP transition state.
  • preferred inhibitors are any of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG.
  • inhibitors are compounds 9-12, 23, 26, or 29, their salts, or their phosphonic acid ester derivatives.
  • this method would be particularly useful for treatment of colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma, or where the cancer tissue expresses thymidine phosphorylase.
  • the treatment would be expected to enhance the effectiveness of a chemotherapeutic nucleoside substrate of the thymidine phosphorylase, e.g., 5-fluoro-2'-deoxyuridine.
  • the present invention is additionally directed to methods of inhibiting angiogenesis in a mammal, the methods comprise administering to the mammal a transition state inhibitor that resembles the charge and geometry of the TP transition state.
  • preferred inhibitors are any of compounds 1-22 of FIG. 2 and compounds 23-29 of FIG. 7, their salts, or their phosphonic acid ester derivatives; more preferred inhibitors are compounds 9-12, 23, 26, and 29, their salts, or their phosphonic acid ester derivatives.
  • any disease characterized by excessive or inappropriate angiogenesis where the angiogenesis is at least partially caused by thymidine phosphorylase, for example cancer, in particular colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma, particularly where the cancer tissue expresses thymidine phosphorylase.
  • thymidine phosphorylase for example cancer, in particular colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma, particularly where the cancer tissue expresses thymidine phosphorylase.
  • diseases characterized by excessive or inappropriate angiogenesis are rheumatoid arthritis, diseases of the retina such as diabetic retinopathy and macular degeneration, atherosclerosis, various diseases of female reproductive organs such as endometriosis, and obesity.
  • Example 1 Determination of The Thymidine Phosphorylase Transition State. Introduction Enzymes can catalyze highly unfavorable reactions by stabilizing the transition state. Thus, unreactive transition state analogues should be powerful inhibitors. For example, a transition state-analogue inhibitor of PNP binds with K ⁇ 10 pM. Determination of the transition state can be accomplished through the use of kinetic isotope effect (KIE) analysis followed by computer modeling. This Example describes the determination of the thymidine phosphorylase transition state by KIE analysis. Materials and Methods
  • radiolabeled thymidine can be enzymatically synthesized from a variety of starting materials, primarily glucose. See, for example, FIG. 3, for a method of labeling thymidine. Determination of kinetic isotope effects (KIEs). KIEs for the radiolabeled positions were measured by mixing the label of interest with a remote label ([5'- 14 C]dT for 3 H KIEs and [4 -
  • 3 H]dT for 14 C KIEs in at least 3:1:: 3 H: 14 C.
  • Sodium arsenate and TP were added and the reaction was allowed to proceed to 20-30% completion and divided into three aliquots.
  • Two aliquots were removed and the unreacted dT was separated from 2-deoxyribose by charcoal chromatography. The remaining aliquot was reacted to 100% completion and separated by charcoal chromatography.
  • the eluted 2-deoxyribose was mixed with scintillation fluid and counted.
  • the 3 H and 14 C spectra were deconvoluted to give an accurate ratio of 3 H to 14 C in both the -25% and 100% reaction mixtures.
  • the measured KIE is defined as in Equation 1.
  • FIG. 4 shows that the arsenolysis of thymidine by TP demonstrates 0.70% commitment to catalysis at 23 ⁇ M TP, hence the experimental and intrinsic KIEs are substantially identical.
  • the intrinsic KIEs are provided in Table 1 and FIG. 5.
  • transition state model provides clear evidence that the transition state is not dissociative or S N l-like as previously assumed.
  • the TS demonstrates an S N 2 type reaction with substantial participation of both the nucleophile and the leaving group.
  • the above model has 0.24 and 0.22 bond order to the leaving group and nucleophile, respectively.
  • the TS is approximately symmetric with substantial bond order to both the attacking nucleophile and the leaving group.
  • the differences in 1-N KIE are explained by some leaving group activation from active site Arg and Lys residues that were not taken into account in the calculations. Inhibitor designs based on this newly-discovered transition state structure will constitute transition state analog inhibitors.
  • Example 2 Designing Thymidine Phosphorylase Inhibitors Using Electron Potential Mapping
  • Compounds shown in FIG. 7 were analyzed for ability to inhibit thymidine phosphorylase and mapped for electron potential.
  • Molekel v4.3 Compounds were minimized in vacuo at HF/3-21G with the pyrimidine ring, or pyrimidine analogue, constrained to a rotational angle similar to that of the calculated transition state (-40.3° dihedral at the HI' — Cl' — Nl — C6 bond). Surfaces were then generated used Molekel' s "compute electron density" function. Electronic potentials were mapped onto this surface with a scale of +0.3 (blue) to -0.7 (red).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The transition state structure of thymidine phosphorylase is provided as a blueprint for design of transition state inhibitors. Several thymidine phosphorylase inhibitors that resemble the charge and geometry of the thymidine phosphorylase transition state are provided. Also provided are methods of inhibiting a thymidine phosphorylase, methods of treating cancer, and methods of inhibiting angiogenesis which utilize the thymidine phosphorylase transition state inhibitors.

Description

AR&E Docket No. 96700/914
TRANSITION STATE STRUCTURE AND INHIBITORS OF THYMIDINE PHOSPHORYLASES
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 60/500,847, filed September 5, 2003.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant GM41916 awarded by the National Institutes of Health.
BACKGROUND OF THE INVENTION
(1) Field of the Invention The present invention generally relates to enzyme inhibitors. More specifically, the invention relates to the transition state structure of thymidine phosphorylase and its use as a blueprint for the design of transition state analog inhibitors of thymidine phosphorylases, the transition state analog inhibitors of thymidine phosphorylase, and methods of using those inhibitors.
(2) Description of the Related Art References cited Aoki T et al. (2002) Correlation between malignancy grade and p53 in relation to thymidine phosphorylase activity in colorectal cancer patients. Oncol. Rep. 9(6): 1267-71. Bainbridge JW et al. (2003) Gene therapy for ocular angiogenesis. Clin. Sci. (Lond) 104(6):561-75. Brown NS, Bicknell R. (1998) Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochemical Journal 334(Pt 1): 1-8, Burke-Gaffney A et al. (2002) Regulation of chemokine expression in atherosclerosis.
Vascul. Pharmacol. 38(5):283-92. Cole C et al. (1999) A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor. Anticancer Drug Des. 14(5):411-20. Crandall DL et al. (1997) A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 4(2) :211-32.
286518.1 Gudas LJ, Ullman B, Cohen A, Martin DW Jr. (1978) Deoxyguanosine toxicity in a mouse T lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell 14(3):531-8. Hotchkiss KA et al. (2003) Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res. 63(2):527-33. Igawa H et al. (2003) Influence of platelet-derived entothelial cell growth factor/thymidine phosphorylase on the cell cycle in head and neck squamous cell carcinoma in vitro. Oncol. Rep. 10(4):967-71. Kicska GA et al. (2001) Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. USA 98(8):4593-8. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA. 92(4):998-1002. Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res. 4(suppl 3):S81- S90. Reynolds LP et al. (2002) Angiogenesis in the female reproductive organs: pathological implications. Int. J. Exp. Pathol. 83(4): 151-63. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam
A, Harris AL, Bicknell R. (1994) Association of ovarian malignancy with expression of platelet- derived endothelial cell growth factor. Journal of the National Cancer Institute. 86(16): 1234-8. Sato J et al. (2003) Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int. J. Cancer 106(6):863-70. Takao S, Akiyama SI, Nakajo A, Yoh H, Kitazono M, Natsugoe S, Mivadera K,
Fukushime M, Yamada Y, Aikou T. (2000) Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Research. 60(19):5345-8. Taylor RN et al. (2002) Angiogenic factors in endometriosis. Ann. NY Acad. Sci. 955:89- 100. Tokunaga Y et al. (2002) Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery 131(5):541. Tsukagoshi S et al. (2003) Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int. J. Oncol. 22(5):961- 7.
286518.1 Nucleoside phosphorylases play an integral role in several types of human cancers. For example, purine nucleoside phosphorylase (PNP) is well known to be essential for the proliferation of T-cells in lymphocytic leukemias (Gudas et al., 1978). More recently, thymidine phosphorylase (aka platelet derived-endothelial cell growth factor; PD-ECGF) has been implicated as a significant contributor to angiogenesis in many solid tumor types (Reynolds et al., 1994). TP expression has been shown to correlate with the aggressiveness and invasiveness of several different types of human tumors, including breast and colon primary cell carcinomas (Moghaddam et al., 1995; Aoki et al., 2002). Additionally, the most potent inhibitor of TP, (TPI - FIG. 7) K = 20 nM), has been shown to have some antiangiogenic activity in vivo (Takao et al., 2000). Thymidine phosphorylase (TP) catalyzes the reversible phosphorolysis of the glycosidic bond of thymidine forming thymine and 2-deoxyribose 1-phosphate (FIG. 1) which is subsequently metabolized to 2-deoxyribose. It is believed that 2-deoxyribose is eventually responsible for the angiogenic effects of TP (Brown & Bicknell, 1998). TP also promotes endothelial cell migration in vitro, also apparently due to 2-deoxyribose (Hotchkiss et al., 2003). In addition to its role in thymidine metabolism and in angiogenesis, TP is the primary enzyme of fluoropyrimidine antimetabolite (for example 5-fluoiO-2'-deoxyuridine [FdUrd]) degradation. The fluoiOpyrimidines are one of the most frequently used chemotherapeutic drugs for the treatment of GI malignancies, including colorectal cancer. One approach used clinically to treat liver metastases arising from colorectal cancer is the hepatic artery infusion of FdUrd.
FdUrd is converted to its active metabolite, FdUMP, by thymidine kinase. The opposing reaction, catalyzed by TP, converts FdUrd to 5-fluorouracil (FUra). Since FUra is 100 to 1000-fold less potent than FdUrd, the metabolism of FdUrd by TP tends to reduce the activity of the anticancer drug. TP inhibitors would thus be useful clinically when used in combination with FrUrd to potentiate its antitumor activity, particularly in more aggressive tumors that express high levels of TP. In addition to cancer, inappropriate induction of angiogenesis plays an important role in other diseases, for example rheumatoid arthritis (Paleolog, 2002), retinal diseases such as diabetic retinopathy and age related macular degeneration (Bainbridge et al., 2003), atherosclerosis (Burke-Gaffnet et al., 2002), various diseases of female reproductive organs such as endometriosis (Reynolds et al., 2002; Taylor et al., 2002), and obesity (Crandall et al., 1997). Thus, there is a need for improved inhibitors of TP. The present invention addresses that need.
286518.1 SUMMARY OF THE INVENTION Accordingly, the inventors have established the transition state structure of thymidine phosphorylase. The transition state structure provides a blueprint to design thymidine phosphorylase inhibitors that resemble that transition state structure. These inhibitors are useful, for example, in inhibiting angiogenesis and in cancer treatments. Thus, in some embodiments, the invention is directed to transition state inhibitors of a thymidine phosphorylase. In these embodiments, the transition state inhibitors are compounds that resemble the charge and geometry of the thymidine phosphorylase transition state. In other embodiments, the invention is directed to methods of inhibiting a thymidine phosphorylase. The methods comprise combining the thymidine phosphorylase with any of the transition state inhibitors described above. Additionally, the invention is directed to methods of treating cancer in a mammal. The methods comprise administering to the mammal any of the transition state inhibitors described above. The invention is also directed to methods of inhibiting angiogenesis in a mammal. These methods also comprise administering to the mammal any of the transition state inhibitors described above. The invention is additionally directed to methods of designing an inhibitor of thymidine phosphorylase. The methods comprise designing a compound that resembles the charge and geometry of the thymidine phosphorylase transition state.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 provides the thymidine phosphorylase reaction. FIG. 2 provides preferred examples of thymidine phosphorylase inhibitors that are transition state analogs. FIG. 3 provides a schematic of chemical methods for synthesizing radiolabeled thymidine. Panel a. Synthesis of ATP from glucose. Panel b. Synthesis of thymidine from ATP. Compounds shown in boldface type are purified. Abbreviations used are: AD, adenosine deaminase; AK, adenylate kinase; AP, alkaline phosphatase; APRT, adenosine phosphoribosyl transferase; G6PDH, G6P dehydrogenase; 6PGDH, 6-phosphogluconate dehydrogenase; HK, hexokinase; PK, pyruvate kinase; PNP, purine nucleoside phosphorylase; PPase, inorganic pyrophosphatase; PRI, phosphoriboisomerase; PRPS, 5-ribosyl-l-pyrophosphate synthesis; RTR, ribonucleotide triphosphate reductase; TP, thymidine phosphorylase. FIG. 4 shows a graph of experimental results of the arsenolysis of thymidine by TP. FIG. 5 shows the intrinsic KIEs of thymidine.
286518.1 FIG. 6 shows the experimentally derived model of the TP transition state structure. FIG. 7 shows examples of compounds subjected to electron potential mapping and determination of ability to inhibit thymidine phosphorylase.
DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the discovery of the transition-state structure of thymidine phosphorylase (TP). The experimental results leading to the discovery of the transition-state structure is described in Example 1. The discovery of the TP transition-state structure allows the design of transition-state analogs that would be expected to be strong inhibitors of TP. This is established by studies of a related enzyme, purine nucleoside phosphorylase (PNP), showing that transition-state analogs having a similar charge and geometry as the transition state compound of an enzyme are likely to be strong inhibitors of that enzyme (Kicska et al. 2001). The transition state of TP, provided in Example 1 below, has a surprising structure, since there is apparently little oxacarbenium charge buildup, whereas the transition state was expected to be an oxacarbenium ion (Cole et al., 1999). Accordingly, in some embodiments, the invention is directed to transition state inhibitors of a thymidine phosphorylase (TP). The transition state inhibitors are compounds that resemble the charge and geometry of the thymidine phosphorylase transition state. Non-limiting examples of TP transition state inhibitors are provided as compounds 1-22 of FIG. 2 and compounds 23-32 of FIG. 7. More preferred inhibitors are compounds 9-12, 23, 26, and 29, because those compounds most closely resemble the TP transition state. The skilled artisan would understand that, although the compounds of FIG. 2 are shown as the phosphonic acid, other salt forms are equally effective, and that they will exist in biological fluids and in buffered aqueous solutions as mixtures of salt and acid forms depending upon the biological fluid or buffer. It would also be understood that the inhibitor compounds of FIG. 2 and FIG. 7 may also be in the form of phosphonic acid ester derivatives and that these will constitute pro-drug forms of these compounds, capable of being converted to the active forms by ester cleavage. As used herein, a compound resembles the charge and geometry of the TP transition state if the compound is as much alike in charge and geometry of the TP transition state as any of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG. 7. The transition state inhibitors of these embodiments would be expected to inhibit a thymidine phosphorylase from any archaeal, bacterial or mammalian species (including humans), since the enzyme is very similar structurally between kingdoms (Cole et al., 1999).
286518.1 The above-described TP transition state inhibitors can be formulated in a pharmaceutically acceptable excipient, for pharmaceutical administration to a mammal, including humans. These formulations can be prepared for administration without undue experimentation for any particular application. The inhibitor compositions can also be prepared alone or in combination with other medications, such as chemotherapeutic agents. Additionally, proper dosages of the inhibitors can be determined without undue experimentation using standard dose- response protocols. Accordingly, the inhibitor compositions designed for oral, lingual, sublingual, buccal and intrabuccal administration can be made without undue experimentation by means well known in the art, for example with an inert diluent or with an edible carrier. The compositions may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the pharmaceutical inhibitor compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. Tablets, pills, capsules, troches and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents. Some examples of binders include microcrystalline cellulose, gum tragacanth or gelatin. Examples of excipients include starch or lactose. Some examples of disintegrating agents include alginic acid, corn starch and the like. Examples of lubricants include magnesium stearate or potassium stearate. An example of a glidant is colloidal silicon dioxide. Some examples of sweetening agents include sucrose, saccharin and the like. Examples of flavoring agents include peppermint, methyl salicylate, orange flavoring and the like. Materials used in preparing these various compositions should be pharmaceutically pure and nontoxic in the amounts used. ' The inhibitor compositions of the present invention can easily be administered parenterally such as for example, by intravenous, intramuscular, intrathecal or subcutaneous injection, either alone or combined with another medication, e.g., a chemotherapeutic agent. Parenteral administration can be accomplished by incorporating the compositions of the present invention into a solution or suspension. Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents. Parenteral formulations may also include antibacterial agents such as for example, benzyl alcohol or methyl parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
286518.1 Rectal administration includes administering the pharmaceutical inhibitor compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas. Suppository formulations can easily be made by methods known in the art. For example, suppository formulations can be prepared by heating glycerin to about 120 °C, dissolving the composition in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold. Transdermal administration includes percutaneous absorption of the inhibitor composition through the skin. Transdermal formulations include patches (such as the well-known nicotine patch), ointments, creams, gels, salves and the like. The present invention includes nasally administering to the mammal a therapeutically effective amount of the inhibitor composition. As used herein, nasally administering or nasal administration includes administering the composition to the mucous membranes of the nasal passage or nasal cavity of the patient. As used herein, pharmaceutical compositions for nasal administration of a composition include therapeutically effective amounts of the composition prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the composition may also take place using a nasal tampon or nasal sponge. In other embodiments, the invention is directed to methods of inhibiting a thymidine phosphorylase with transition state analogs. The methods comprise combining the thymidine phosphorylase with any transition state inhibitor that resembles the charge and geometry of the TP transition state. In some embodiments, the inhibitor is first designed to resemble the transition state and then synthesized. In preferred embodiments, the transition state inhibitor is one of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG. 7, their salts, or their phosphonic acid ester derivatives. More preferably, the transition state inhibitor is one of compounds 9-12, 23, 26, or 29, their salts, or their phosphonic acid ester derivatives. Although these methods could utilize any thymidine phosphorylase, i.e., from any bacterial, archaeal, or eukaryotic species, it is preferred that the thymidine phosphorylase is a mammalian, and most preferably a human thymidine phosphorylase, since the enzyme has a clear effect on mammalian angiogenesis, and is associated with human disease, in particular cancer. Consequently, although these methods could be utilized with thymidine phosphorylases in vitro, it would be expected that the methods would have their greatest usefulness with thymidine phosphorylases in a living cell, most preferably a cell that is part of a living mammal. It is anticipated that the method would be particularly useful in humans with a disease associated with inappropriate induction of angiogenesis, for example cancer, in particular colon cancer, colorectal cancer, gastrointestinal cancer, and adenocarcinoma (Aoki et al., 2002; Tokunaga et al.,
286518.1 2002; Tsukagoshi et al., 2003; Sato et al., 2003), where thymidine phosphorylase activity is associated with more virulent phenotypes and/or resistance to chemotherapeutic agents that are TP substrates. Thus, in preferred embodiments, the cancer tissue expresses thymidine phosphorylase (Igawa et al., 2003). In other preferred embodiments, the human is being treated with a chemotherapeutic nucleoside substrate of the thymidine phosphorylase, e.g., 5-fluoro-2'- deoxyuridine. The human in need of inhibition of thymidine phosphorylase can alternatively have a disease characterized by excessive or inappropriate angiogenesis, for example rheumatoid arthritis, retinal diseases such as diabetic retinopathy and age related macular degeneration, atherosclerosis, various diseases of female reproductive organs such as endometriosis, or obesity. In related embodiments, the invention is directed to methods of treating cancer in a mammal. The methods comprise administering to the mammal a transition state inhibitor that resembles the charge and geometry of the TP transition state. As with previous embodiments, preferred inhibitors are any of compounds 1-22 of FIG. 2 or compounds 23-32 of FIG. 7, their salts, or their phosphonic acid ester derivatives; more preferred inhibitors are compounds 9-12, 23, 26, or 29, their salts, or their phosphonic acid ester derivatives. As discussed in relation to embodiments described above, it is expected that this method would be particularly useful for treatment of colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma, or where the cancer tissue expresses thymidine phosphorylase. Also, the treatment would be expected to enhance the effectiveness of a chemotherapeutic nucleoside substrate of the thymidine phosphorylase, e.g., 5-fluoro-2'-deoxyuridine. The present invention is additionally directed to methods of inhibiting angiogenesis in a mammal, the methods comprise administering to the mammal a transition state inhibitor that resembles the charge and geometry of the TP transition state. As with previous embodiments, preferred inhibitors are any of compounds 1-22 of FIG. 2 and compounds 23-29 of FIG. 7, their salts, or their phosphonic acid ester derivatives; more preferred inhibitors are compounds 9-12, 23, 26, and 29, their salts, or their phosphonic acid ester derivatives. These methods would be effective with any disease characterized by excessive or inappropriate angiogenesis, where the angiogenesis is at least partially caused by thymidine phosphorylase, for example cancer, in particular colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma, particularly where the cancer tissue expresses thymidine phosphorylase. Examples of other diseases characterized by excessive or inappropriate angiogenesis are rheumatoid arthritis, diseases of the retina such as diabetic retinopathy and macular degeneration, atherosclerosis, various diseases of female reproductive organs such as endometriosis, and obesity.
286518.1 Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims, which follow the examples.
Example 1. Determination of The Thymidine Phosphorylase Transition State. Introduction Enzymes can catalyze highly unfavorable reactions by stabilizing the transition state. Thus, unreactive transition state analogues should be powerful inhibitors. For example, a transition state-analogue inhibitor of PNP binds with K < 10 pM. Determination of the transition state can be accomplished through the use of kinetic isotope effect (KIE) analysis followed by computer modeling. This Example describes the determination of the thymidine phosphorylase transition state by KIE analysis. Materials and Methods
Synthesis of labeled thymidines. In the case of TP, radiolabeled thymidine can be enzymatically synthesized from a variety of starting materials, primarily glucose. See, for example, FIG. 3, for a method of labeling thymidine. Determination of kinetic isotope effects (KIEs). KIEs for the radiolabeled positions were measured by mixing the label of interest with a remote label ([5'-14C]dT for 3H KIEs and [4 -
3H]dT for 14C KIEs) in at least 3:1:: 3H:14C. Sodium arsenate and TP were added and the reaction was allowed to proceed to 20-30% completion and divided into three aliquots. Two aliquots were removed and the unreacted dT was separated from 2-deoxyribose by charcoal chromatography. The remaining aliquot was reacted to 100% completion and separated by charcoal chromatography. The eluted 2-deoxyribose was mixed with scintillation fluid and counted. The 3H and 14C spectra were deconvoluted to give an accurate ratio of 3H to 14C in both the -25% and 100% reaction mixtures. The measured KIE is defined as in Equation 1.
286518.1
Figure imgf000011_0001
Equation 1. In the case of [l-15N]dT, HPLC was used to separate substrate from products and the ratio of isotopes was determined by electrospray ionization mass spectrometry. The [l-15N]dT KIE was calculated by observing thymine. The [l'-14C] KIE was corrected for the KIE of the remote label used ([4'-3H]dT) and the [l-15N]dT KIE was corrected for natural abundance isotope enrichment of the 'unlabeled' compound. All KIEs were then corrected for isotopic depletion according to Equation 2. r/rτ, , „ τ ττ_, . fraction converted KIE actual = lnd - KIEmeas ) X ln(l - traction converted) Equation 2
Results
Commitment to catalysis. Reaction reversibility and commitment to catalysis are typically the most important sources of KIE suppression. In this study, enzymatic reversibility was prevented by the use of arsenate as the attacking nucleophile in place of phosphate. Commitment to catalysis, which describes the tendency of bound substrate to either proceed to product or to be released into solution, was measured. High commitment to catalysis (all bound substrate proceeds to product) will suppress the experimental KIE. FIG. 4 shows that the arsenolysis of thymidine by TP demonstrates 0.70% commitment to catalysis at 23 μM TP, hence the experimental and intrinsic KIEs are substantially identical. The intrinsic KIEs are provided in Table 1 and FIG. 5.
286518.1 Position Intrinsic KIE 1 '-3H 0.982± 0.002 V-14C 1 .146± 0.005 2'fl-3H 0.967± 0.002 2'S-3H 1 .043± 0.002 4'-3H 1 .027± 0.003 5'-3H 1.068± 0.003 5'-14C 1 .000* 1 -15N 1.021 ± 0.005 * KIE assumed to be unity. Table 1. Transition state calculations. The TS structure was modeled using density functional theory
(B1LYP/6-31G*) as implemented in Gaussian 98. A starting structure was determined using the Synchronous Transit-Guided Quasi-Newton method with no constraints. Theoretical KIEs were then calculated using Isoeff98. Constraints were then added, the TS redetermined using the Berny Algorithm, and KIEs were again calculated. The constraints are varied in a systematic manner until the calculated KEs approximately match those measured. The structure provided in FIG. 6 is considered to be the TS. Final distance constraints were between 1-N and l'-C, l'-C and O(phosphate), and l'-C and l'-H. The last constraint was added to regulate out-of-plane vibrations. The calculated and intrinsic KIEs, along with the ΔKIE for each position are provided in Table 2.
286518.1 Position Calculated KIE Intrinsic KIE AKIE 1'-3H 0.981 0.982± 0.002 0.001 1'-14C 1.144 1.146+ 0.005 0.002 5 2'fl-3H 0.941 0.967± 0.002 0.026 2'S-3H 1.026 1 .043± 0.002 0.017 4'-3H 1.046 1.027+ 0.003 0.019 5'-3H 1.066* 1.068± 0.003 0.002 5'-14C 1.001 1.000 0.001 ιo 1 -15N 1.012 1.021 ± 0.005 0.009 * Average of 5' roR - and 5'proS-3H
Table 2. Conclusions The transition state model provided herein provides clear evidence that the transition state is not dissociative or SNl-like as previously assumed. The TS demonstrates an SN2 type reaction with substantial participation of both the nucleophile and the leaving group. The above model has 0.24 and 0.22 bond order to the leaving group and nucleophile, respectively. Based on these novel results, the TS is approximately symmetric with substantial bond order to both the attacking nucleophile and the leaving group. There appears to be little oxocarbenium charge buildup. The differences in 1-N KIE are explained by some leaving group activation from active site Arg and Lys residues that were not taken into account in the calculations. Inhibitor designs based on this newly-discovered transition state structure will constitute transition state analog inhibitors.
Example 2. Designing Thymidine Phosphorylase Inhibitors Using Electron Potential Mapping Compounds shown in FIG. 7 were analyzed for ability to inhibit thymidine phosphorylase and mapped for electron potential. Experimental: Binding constants were determined by UV-Vis spectrophotometery using 2'-deoxy-5-nitrouridine (5NdU) as the substrate (Km = 50 μM at pH 6.01). The reaction mixture consisted of inhibitor (approximately 1/10 x Kλ to 10 x K,), 50 mM MES (pH 6.01), 150 mM NaCl, 1 mM EDTA, 5 mM inorganic phosphate, and 250 μM 5NdU in a total of 1 ml. Thymidine phosphorylase was added to approximately 10 nM (1 nM enzyme was used for D723333-P) and the reaction was monitored at λ = 347 nm for 30 min. At least five concentrations of inhibitor were used for each compound and experiments were repeated in triplicate. Initial rates were
286518.1 determined by a linear least-squares fit. The K\ for each compound was then determined using the following equation:
Figure imgf000014_0001
where v is the rate of reaction and V is the maximal rate in the absence of inhibitor. Computational: Maps of electron potential density were constructed using Gaussian98 and
Molekel v4.3. Compounds were minimized in vacuo at HF/3-21G with the pyrimidine ring, or pyrimidine analogue, constrained to a rotational angle similar to that of the calculated transition state (-40.3° dihedral at the HI' — Cl' — Nl — C6 bond). Surfaces were then generated used Molekel' s "compute electron density" function. Electronic potentials were mapped onto this surface with a scale of +0.3 (blue) to -0.7 (red). hi view of the above, it will be seen that the several advantages of the invention are achieved and other advantages attained. As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense. All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.
286518.1

Claims

What is claimed is: 1. A transition state inhibitor of a thymidine phosphorylase, wherein the transition state inhibitor is a compound that resembles the charge and geometry of the thymidine phosphorylase transition state.
2. The transition state inhibitor of claim 1 , selected from the group consisting of compounds 1-22 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
3. The transition state inhibitor of claim 1, selected from the group consisting of compounds 9- 12 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
4. The transition state inhibitor of claim 1, selected from the group consisting of compounds 23-29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
5. The transition state inhibitor of claim 1 , selected from the group consisting of compounds 30-32 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
6. The transition state inhibitor of claim 1, selected from the group consisting of compounds 23, 26, and 29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
7. The transition state inhibitor of claim 1, in a pharmaceutically acceptable excipient.
8. A method of inhibiting a thymidine phosphorylase, the method comprising combining the thymidine phosphorylase with the transition state inhibitor of claim 1.
9. The method of claim 8, wherein the transition state inhibitor is selected from the group consisting of compounds 1-22 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
10. The method of claim 8, wherein the transition state inhibitor is selected from the group consisting of compounds 9-12 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
11. The method of claim 8, wherein the transition state inhibitor is selected from the group consisting of compounds 23-29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
286518.1
12. The method of claim 8, wherein the transition state inhibitor is selected from the group consisting of compounds 30-32 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
13. The method of claim 8, wherein the transition state inhibitor is selected from the group consisting of compounds 23, 26, and 29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
14. The method of claim 8, wherein the thymidine phosphorylase is a mammalian thymidine phosphorylase.
15. The method of claim 8, wherein the thymidine phosphorylase is a human thymidine phosphorylase.
16. The method of claim 8, wherein the thymidine phosphorylase is in a living cell.
17. The method of claim 16, wherein the cell is part of a living mammal.
18. The method of claim 17, wherein the mammal is a human with cancer.
19. The method of claim 18, wherein the cancer is colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma.
20. The method of claim 18, wherein the cancer tissue expresses thymidine phosphorylase.
21. The method of claim 18, wherein the human is being treated with a chemotherapeutic nucleoside substrate of the thymidine phosphorylase.
22. The method of claim 21, wherein the chemotherapeutic nucleoside is 5-fluoro-2'- deoxyuridine.
23. A method of treating cancer in a mammal, the method comprising administering to the mammal the transition state inhibitor of claim 1.
286518.1
24. The method of claim 23, wherein the transition state inhibitor is selected from the group consisting of compounds 1-22 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
25. The method of claim 23, wherein the transition state inhibitor is selected from the group consisting of compounds 9- 12 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
26. The method of claim 23, wherein the transition state inhibitor is selected from the group consisting of compounds 23-29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
27. The method of claim 23, wherein the transition state inhibitor is selected from the group consisting of compounds 30-32 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
28. The method of claim 23, wherein the transition state inhibitor is selected from the group consisting of compounds 23, 26, and 29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
29. The method of claim 23, wherein the cancer is colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma.
30. The method of claim 23, wherein the cancer tissue expresses thymidine phosphorylase.
31. The method of claim 23, wherein the mammal is a human is being treated with a chemotherapeutic nucleoside substrate of the thymidine phosphorylase.
32. The method of claim 31, wherein the chemotherapeutic nucleoside is 5-fluoro-2'- deoxyuridine.
33. A method of inhibiting angiogenesis in a mammal, the method comprising administering to the mammal the transition state inhibitor of claim 1.
286518.1
34. The method of claim 33, wherein the transition state inhibitor is selected from the group consisting of compounds 1-22 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
35. The method of claim 33, wherein the transition state inhibitor is selected from the group consisting of compounds 9-12 of FIG. 2, their salts, and their phosphonic acid ester derivatives.
36. The method of claim 33, wherein the transition state inhibitor is selected from the group consisting of compounds 23-29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
37. The method of claim 33, wherein the transition state inhibitor is selected from the group consisting of compounds 30-32 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
38. The method of claim 33, wherein the transition state inhibitor is selected from the group consisting of compounds 23, 26, and 29 of FIG. 7, their salts, and their phosphonic acid ester derivatives.
39. The method of claim 33, wherein the mammal is a human with cancer.
40. The method of claim 39, wherein the cancer is colon cancer, colorectal cancer, gastrointestinal cancer, or adenocarcinoma.
41. The method of claim 39, wherein the cancer tissue expresses thymidine phosphorylase.
42. The method of claim 33, wherein the mammal is a human with rheumatoid arthritis.
43. The method of claim 33, wherein the mammal is a human with a disease of the retina characterized by excessive angiogenesis.
44. The method of claim 33, wherein the mammal is a human with atherosclerosis.
286518.1
45. The method of claim 33, wherein the mammal is a human with endometriosis.
46. The method of claim 33, wherein the mammal is an obese human.
47. A method of designing an inhibitor of thymidine phosphorylase, the method comprising designing a compound that resembles the charge and geometry of the thymidine phosphorylase transition state.
286518.1
PCT/US2004/028703 2003-09-05 2004-09-03 Transition state structure and inhibitors of thymidine phosphorylases WO2005026131A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04783065A EP1673353A4 (en) 2003-09-05 2004-09-03 Transition state structure and inhibitors of thymidine phosphorylases
US10/570,475 US20070275988A1 (en) 2003-09-05 2004-09-03 Transition state structure and inhibitors of thymidine phosphorylases
JP2006525465A JP2007504246A (en) 2003-09-05 2004-09-03 Transition state structures and inhibitors of thymidine phosphorylase.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50084703P 2003-09-05 2003-09-05
US60/500,847 2003-09-05

Publications (1)

Publication Number Publication Date
WO2005026131A1 true WO2005026131A1 (en) 2005-03-24

Family

ID=34312226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/028703 WO2005026131A1 (en) 2003-09-05 2004-09-03 Transition state structure and inhibitors of thymidine phosphorylases

Country Status (4)

Country Link
US (1) US20070275988A1 (en)
EP (1) EP1673353A4 (en)
JP (1) JP2007504246A (en)
WO (1) WO2005026131A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2204175A1 (en) * 2007-10-11 2010-07-07 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
EP2204192A1 (en) * 2007-10-11 2010-07-07 Taiho Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016291A2 (en) * 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
CN101094080B (en) * 2006-06-22 2012-06-20 华为技术有限公司 Charging method for system of putting call through immediately after connection
EP2049543B1 (en) * 2006-09-07 2014-11-05 Callaghan Innovation Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
DK2114925T3 (en) * 2006-12-22 2012-05-29 Ind Res Ltd Azetidine analogs of nucleosidase and phosphorylase inhibitors
US11114184B2 (en) 2017-02-21 2021-09-07 Albert Einstein College Of Medicine DNA methyltransferase 1 transition state structure and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124054A1 (en) * 2001-01-23 2003-07-03 Jun Toyohara Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0763529T3 (en) * 1995-03-29 2003-11-10 Taiho Pharmaceutical Co Ltd Uracil derivatives and anti-tumor potentiator and anti-tumor agent containing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124054A1 (en) * 2001-01-23 2003-07-03 Jun Toyohara Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2204175A1 (en) * 2007-10-11 2010-07-07 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
EP2204192A1 (en) * 2007-10-11 2010-07-07 Taiho Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
CN101820914A (en) * 2007-10-11 2010-09-01 大鹏药品工业株式会社 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
EP2204192A4 (en) * 2007-10-11 2011-12-21 Taiho Pharmaceutical Co Ltd Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
EP2204175A4 (en) * 2007-10-11 2012-02-29 Taiho Pharmaceutical Co Ltd Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
US8188105B2 (en) 2007-10-11 2012-05-29 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient
AU2008310480B2 (en) * 2007-10-11 2013-01-17 Taiho Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient
AU2008310481B2 (en) * 2007-10-11 2013-05-23 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient

Also Published As

Publication number Publication date
US20070275988A1 (en) 2007-11-29
EP1673353A1 (en) 2006-06-28
EP1673353A4 (en) 2007-03-28
JP2007504246A (en) 2007-03-01

Similar Documents

Publication Publication Date Title
JP5357857B2 (en) Anticancer agent and DNA replication inhibitor
WO2000076524A1 (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
JP2013173745A (en) Method for treating cancer
Alzahrani et al. 5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer
US20220145304A1 (en) Modified micrornas and their use in the treatment of cancer
US20070275988A1 (en) Transition state structure and inhibitors of thymidine phosphorylases
US20140080768A1 (en) Prodrugs of dhodh inhibitors and their uses
Weber et al. Targeting signal transduction
US20200054661A1 (en) Multitargeted nucleoside derivatives
JPH0660103B2 (en) Composition for treating tumor with UDPG
US20020183277A1 (en) Combination of vitamin D analogue and pyrimidine nucleoside analogue
WO2018121669A1 (en) Pharmaceutical composition for treating cancer and use thereof
CN109152791A (en) The method of -2 &#39; of the fluoro- 5- azepine of 2 &#39;, 2 &#39;-two-deoxycytidine or its prodrug treatment TP53 wild type tumor
Pizzorno et al. Pyrimidine analogs
Bandyopadhyay et al. Key Enzymes in Cancer: Mechanism of Action and Inhibition With Anticancer Agents
JPH0717869A (en) Antitumor effect enhancer containing 5-phenethyl-2&#39;-deoxyuridine and antitumor agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006525465

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004783065

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004783065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10570475

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10570475

Country of ref document: US